FDA Reviewers Find Gilead’s Quad Effective, But Point to Renal Concerns
Gilead Sciences’ Quad HIV candidate appears to be effective in treating HIV but FDA reviewers are concerned about a number of renal adverse events reported in two Phase III trials, according to agency documents.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.